Moderna has reported positive interim results from the Phase I clinical trial of its Covid-19 vaccine candidate, mRNA-1273, led by the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID).
The company recorded immunogenicity data for the 25µg and 100µg dose levels following two doses (day 43) and at the 250µg dose level after one dose (day 29).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Results showed dose dependent increases in immunogenicity across the three dose levels, as well as between prime and boost with the 25µg and 100µg dose levels.
